Podcast: Cell Therapy Firm Stempeutics' CEO On Japan Partnerships, India Trials Regulation Changes

CEO of cell therapy firm Stempeutics BN Manohar speaks to Scrip about partnering with Japanese firms for India’s first allogenic cell therapy Stempeucel. Amid a tough funding environment, AI and new manufacturing tech will drive savings as the company pursues new indications and changes in Indian regulation on clinical trials could make the CGT journey easier, he says in the interview.

Scrip Podcast Special
Stempeutics CEO BN Manohar Speaks To Scrip

Stempeutics Research Pvt. Ltd. commercialized India’s first allogenic stem cell therapy Stempeucel after the Drugs Controller General of India granted manufacturing and marketing approval for treatment of Critical Limb Ischemia (CLI) due to Buerger’s disease and CLI due to atherosclerotic peripheral arterial disease.

The Mesenchymal Stromal Cells (MSCs) product was later also approved in India to treat knee osteoarthritis (OA) and diabetic foot...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip